VER-01 Cannabinoid Drug Wins FDA Breakthrough Therapy Designation

In a major step forward for chronic pain treatment, the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, an investigational cannabinoid-based medicine from Vertanical. The German biopharmaceutical company focuses on innovative therapies for chronic pain, and this regulatory nod highlights the drug’s potential as a meaningful alternative to existing options.

VER-01 is a standardized full-spectrum extract made from a specific strain of Cannabis sativa known as DKJ127 L. It delivers a consistent blend of cannabinoids, terpenes, and other bioactive compounds in a pharmaceutical-grade oral formulation. Unlike variable cannabis products, this extract is designed for reliable dosing and reproducible effects in patients with chronic pain.

The FDA’s decision rests on data from two large Phase 3 clinical trials that showed clear benefits in pain relief and tolerability. These results convinced regulators that VER-01 demonstrates the kind of preliminary evidence needed for expedited development and review.

One placebo-controlled study enrolled 820 patients with chronic low back pain. Participants taking VER-01 experienced an average pain score reduction of 1.9 points on a standard numeric rating scale after 12 weeks. The improvement strengthened over time, reaching 2.9 points by the six-month mark. Benefits held steady with continued treatment, and patients also noted better sleep quality and physical function compared with those on placebo.

A second study directly compared VER-01 with opioids in 384 patients. VER-01 delivered stronger pain relief, with a 2.5-point average reduction versus roughly 2.1 points for opioids. Patients on VER-01 also showed better overall tolerability during the treatment period.

Together, the trials point to consistent, clinically relevant pain reduction alongside a favorable safety profile. No evidence of dependence or withdrawal symptoms appeared across the program, which stands out in a treatment area often limited by opioid-related risks.

Breakthrough Therapy Designation is reserved for investigational drugs that treat serious conditions and show early signs they may offer substantial improvement over available therapies. It gives developers more frequent FDA guidance and a faster review timeline. For VER-01, the designation recognizes its promise as a non-opioid option at a time when better chronic pain solutions remain a pressing public health need.

Vertanical is not standing still. The company has marketing authorization applications under review in multiple European countries and expects decisions in the coming period. In the United States, an additional pivotal Phase 3 trial is already underway to support a future regulatory submission.

Dr. Clemens Fischer, founder of Vertanical, called the designation an important milestone. “The FDA’s breakthrough therapy designation for VER-01 is a major recognition of its potential to address the significant unmet need in chronic pain,” he said. “Patients have waited far too long for meaningful progress. We believe VER-01 has the potential to change how chronic pain is treated and offer physicians a much-needed non-opioid solution.”

Chronic pain touches hundreds of millions of people worldwide and often leaves patients with limited choices. Opioids remain widely used despite well-known drawbacks, while many other treatments fall short for moderate to severe cases. A well-studied, standardized cannabinoid extract that shows sustained benefits and good tolerability could fill an important gap.

The FDA’s action accelerates the path forward for VER-01 while European reviews continue. If later data and approvals confirm the early promise, patients and doctors could gain access to a new class of therapy grounded in rigorous clinical evidence. For now, the Breakthrough Therapy Designation sends a clear signal that regulators see real potential in this cannabinoid-based approach to chronic pain.